×
About 142,936 results

ALLMedicine™ Schizophrenia Center

Research & Reviews  67,619 results

Attractor cortical neurodynamics, schizophrenia, and depression.
https://doi.org/10.1038/s41398-021-01333-7 10.1093/acprof:oso/9780199587865.001.0001 10.1093/acprof:oso/9780198784852.001.0001 10.1016/j.pneurobio.2009.01.006 10.1016/j.pneurobio.2012.01.010 10.1371/journal.pcbi.0030228 10.1055/s-2007-990304 10.1038/nrn2462 10.1016/j.pbb.2011.06.017 10.1093/braincomms/fcaa196 10.1016/j.neubiorev.2016.05.007 10.1073/pnas.79.8.2554 10.1088/0954-898X_2_4_004 10.1088/0305-4470/24/11/029 10.1016/j.brainres.2011.08.002 10.1111/j.1460-9568.2006.04940.x 10.1371/journal.pone.0023630 10.1016/j.pneurobio.2011.08.002 10.1007/s00422-007-0149-1 10.1016/j.neubiorev.2010.09.001 10.1016/j.tins.2004.08.002 10.1016/j.biopsych.2008.05.015 10.1023/A:1011204814320 10.1152/jn.01095.2004 10.1111/j.1460-9568.2008.06379.x 10.1111/pcn.12823 10.1016/B978-0-444-63639-3.00025-6 10.1176/appi.ajp.2017.16070814 10.1002/wps.20693 10.2147/NDT.S225643 10.1016/j.schres.2017.01.050 10.1016/j.neuropharm.2019.03.001 10.1192/bjp.151.2.145 10.1176/ajp.153.3.321 10.1016/S0140-6736(04)16458-1 10.1016/S0140-6736(15)01121-6 10.1176/jnp.6.4.348 10.1016/S0006-3223(99)00130-4 10.1016/j.neuron.2012.12.032 10.1098/rstb.1996.0129 10.1196/annals.1300.020 10.1007/s10571-006-9062-8 10.31887/DCNS.2010.12.3/jcoyle 10.1093/schbul/sbs076 10.1016/j.coph.2014.12.004 10.1016/j.neuroscience.2012.04.044 10.1001/jamapsychiatry.2014.1582 10.1124/pr.115.010512 10.1523/JNEUROSCI.2486-17.2018 10.1192/bjpo.bp.117.005058 10.1176/appi.ajp.159.6.1018 10.1093/schbul/sbj082 10.1523/JNEUROSCI.4636-06.2007 10.1093/acprof:oso/9780198570035.001.0001 10.1007/s00429-019-01945-2 10.1093/oso/9780198845997.001.0001 10.1038/nrn1648 10.1016/j.neuroscience.2013.06.008 10.1016/j.conb.2013.11.003 10.1038/npp.2009.116 10.1016/j.schres.2014.09.041 10.1111/bph.13850 10.1073/pnas.98.1.301 10.1016/j.pneurobio.2004.05.006 10.1016/S0893-6080(02)00049-7 10.1016/j.biopsych.2016.05.022 10.1038/s41398-021-01197-x 10.1016/j.neuroimage.2019.116189 10.1093/cercor/bhz161 10.1093/schbul/sbw220 10.1093/brain/awl004 10.1007/s00429-013-0546-2 10.1002/cne.21346 10.1177/2398212817723443 10.1002/hipo.23171 10.1016/j.pneurobio.2018.09.004 10.1016/j.cortex.2013.08.002 10.1093/brain/awt162 10.1016/j.nbd.2012.01.015 10.1007/BF00235545 10.1016/S1053-8119(03)00393-8 10.1038/82959 10.1016/j.tics.2010.12.004 10.1162/089892904322926791 10.1136/jnnp.57.12.1518 10.1111/j.1749-6632.2011.06229.x 10.1176/appi.ajp.2008.08050721 10.1098/rstb.2012.0407 10.1016/j.tics.2011.12.011 10.1016/j.biopsych.2010.01.027 10.1177/1754073913477514 10.1016/j.neubiorev.2017.02.013 10.1016/j.neuropsychologia.2017.09.021 10.3389/fnhum.2013.00074 10.1038/mp.2014.163 10.1046/j.1460-9568.2003.02779.x 10.1093/brain/aww255 10.1093/scan/nsaa014 10.1016/j.cortex.2019.10.012 10.1093/cercor/bhy236 10.1038/s41398-018-0139-1 10.1093/scan/nsy032 10.1001/jamapsychiatry.2018.1941 10.1016/j.neuroimage.2020.116845 10.3389/fpsyg.2020.00655 10.1016/j.neuroimage.2015.07.075
Translational Psychiatry; Rolls ET

Apr 13th, 2021 - The local recurrent collateral connections between cortical neurons provide a basis for attractor neural networks for memory, attention, decision-making, and thereby for many aspects of human behavior. In schizophrenia, a reduction of the firing r...

Stigma towards schizophrenia in Cyprus: Does studying a mental health related programme...
https://doi.org/10.1177/00207640211010208
The International Journal of Social Psychiatry; Nikolaou E, Petkari E

Apr 13th, 2021 - Students from mental health related programmes may display stigmatising attitudes towards people of schizophrenia, however there are no data available on this population in Cyprus. The purpose of the present study was (a) to examine the levels of ...

Aripiprazole IM depot as an option for the treatment of bipolar disorder.
https://doi.org/10.1080/14656566.2021.1910236
Expert Opinion on Pharmacotherapy; Kotzalidis GD, Rapinesi C et. al.

Apr 13th, 2021 - Introduction: Long-acting injectable (LAI) antipsychotic drugs are developed to reduce daily intake need and to overcome treatment non-adherence. Aripiprazole IM depot refers to two long-acting aripiprazole formulations, once monthly monohydrate (...

Schizophrenia hospitalization in the US 2005-2014: Examination of trends in demographic...
https://doi.org/10.1097/MD.0000000000025206
Medicine Chen E, Bazargan-Hejazi S et. al.

Apr 13th, 2021 - Primarily we aimed to examine the crude and standardized schizophrenia hospitalization trend from 2005 to 2014. We hypothesized that there will be a statistically significant linear trend in hospitalization rates for schizophrenia from 2005 to 201...

see more →

Guidelines  45 results

The American Psychiatric Association Practice Guideline for the Treatment of Patients W...
https://doi.org/10.1176/appi.ajp.2020.177901
The American Journal of Psychiatry; Keepers GA, Fochtmann LJ et. al.

Sep 1st, 2020 - The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.|2020|Keepers GA,Fochtmann LJ,Anzia JM,Benjamin S,Lyness JM,|methods,methods,methods,classification,therapeutic use,diagnosis,therapy,

CAPLYTA® (lumateperone) | Now Approved | caplyta.com‎
https://www.caplyta.com/‎

Jan 13th, 2020 - Learn about a new treatment. See full safety information, PI, and boxed warning. Get information about this orally administered capsule. Press Release. Prescribing Information. MOA. Important Safety Info. Dosing & Administration.

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated r...
https://doi.org/10.1177/0269881119889296
Journal of Psychopharmacology (Oxford, England); Barnes TR, Drake R et. al.

Dec 12th, 2019 - These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, i...

Cannabidiol as a potential treatment for psychosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843725/
Therapeutic Advances in Psychopharmacology; Davies C,et al

Nov 7th, 2019 - Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treat...

U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
http://www.noven.com/PR101519.php

Oct 14th, 2019 - Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration (FDA) has approved SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch fo...

see more →

Drugs  1,679 results see all →

Clinicaltrials.gov  70,889 results

Attractor cortical neurodynamics, schizophrenia, and depression.
https://doi.org/10.1038/s41398-021-01333-7 10.1093/acprof:oso/9780199587865.001.0001 10.1093/acprof:oso/9780198784852.001.0001 10.1016/j.pneurobio.2009.01.006 10.1016/j.pneurobio.2012.01.010 10.1371/journal.pcbi.0030228 10.1055/s-2007-990304 10.1038/nrn2462 10.1016/j.pbb.2011.06.017 10.1093/braincomms/fcaa196 10.1016/j.neubiorev.2016.05.007 10.1073/pnas.79.8.2554 10.1088/0954-898X_2_4_004 10.1088/0305-4470/24/11/029 10.1016/j.brainres.2011.08.002 10.1111/j.1460-9568.2006.04940.x 10.1371/journal.pone.0023630 10.1016/j.pneurobio.2011.08.002 10.1007/s00422-007-0149-1 10.1016/j.neubiorev.2010.09.001 10.1016/j.tins.2004.08.002 10.1016/j.biopsych.2008.05.015 10.1023/A:1011204814320 10.1152/jn.01095.2004 10.1111/j.1460-9568.2008.06379.x 10.1111/pcn.12823 10.1016/B978-0-444-63639-3.00025-6 10.1176/appi.ajp.2017.16070814 10.1002/wps.20693 10.2147/NDT.S225643 10.1016/j.schres.2017.01.050 10.1016/j.neuropharm.2019.03.001 10.1192/bjp.151.2.145 10.1176/ajp.153.3.321 10.1016/S0140-6736(04)16458-1 10.1016/S0140-6736(15)01121-6 10.1176/jnp.6.4.348 10.1016/S0006-3223(99)00130-4 10.1016/j.neuron.2012.12.032 10.1098/rstb.1996.0129 10.1196/annals.1300.020 10.1007/s10571-006-9062-8 10.31887/DCNS.2010.12.3/jcoyle 10.1093/schbul/sbs076 10.1016/j.coph.2014.12.004 10.1016/j.neuroscience.2012.04.044 10.1001/jamapsychiatry.2014.1582 10.1124/pr.115.010512 10.1523/JNEUROSCI.2486-17.2018 10.1192/bjpo.bp.117.005058 10.1176/appi.ajp.159.6.1018 10.1093/schbul/sbj082 10.1523/JNEUROSCI.4636-06.2007 10.1093/acprof:oso/9780198570035.001.0001 10.1007/s00429-019-01945-2 10.1093/oso/9780198845997.001.0001 10.1038/nrn1648 10.1016/j.neuroscience.2013.06.008 10.1016/j.conb.2013.11.003 10.1038/npp.2009.116 10.1016/j.schres.2014.09.041 10.1111/bph.13850 10.1073/pnas.98.1.301 10.1016/j.pneurobio.2004.05.006 10.1016/S0893-6080(02)00049-7 10.1016/j.biopsych.2016.05.022 10.1038/s41398-021-01197-x 10.1016/j.neuroimage.2019.116189 10.1093/cercor/bhz161 10.1093/schbul/sbw220 10.1093/brain/awl004 10.1007/s00429-013-0546-2 10.1002/cne.21346 10.1177/2398212817723443 10.1002/hipo.23171 10.1016/j.pneurobio.2018.09.004 10.1016/j.cortex.2013.08.002 10.1093/brain/awt162 10.1016/j.nbd.2012.01.015 10.1007/BF00235545 10.1016/S1053-8119(03)00393-8 10.1038/82959 10.1016/j.tics.2010.12.004 10.1162/089892904322926791 10.1136/jnnp.57.12.1518 10.1111/j.1749-6632.2011.06229.x 10.1176/appi.ajp.2008.08050721 10.1098/rstb.2012.0407 10.1016/j.tics.2011.12.011 10.1016/j.biopsych.2010.01.027 10.1177/1754073913477514 10.1016/j.neubiorev.2017.02.013 10.1016/j.neuropsychologia.2017.09.021 10.3389/fnhum.2013.00074 10.1038/mp.2014.163 10.1046/j.1460-9568.2003.02779.x 10.1093/brain/aww255 10.1093/scan/nsaa014 10.1016/j.cortex.2019.10.012 10.1093/cercor/bhy236 10.1038/s41398-018-0139-1 10.1093/scan/nsy032 10.1001/jamapsychiatry.2018.1941 10.1016/j.neuroimage.2020.116845 10.3389/fpsyg.2020.00655 10.1016/j.neuroimage.2015.07.075
Translational Psychiatry; Rolls ET

Apr 13th, 2021 - The local recurrent collateral connections between cortical neurons provide a basis for attractor neural networks for memory, attention, decision-making, and thereby for many aspects of human behavior. In schizophrenia, a reduction of the firing r...

Stigma towards schizophrenia in Cyprus: Does studying a mental health related programme...
https://doi.org/10.1177/00207640211010208
The International Journal of Social Psychiatry; Nikolaou E, Petkari E

Apr 13th, 2021 - Students from mental health related programmes may display stigmatising attitudes towards people of schizophrenia, however there are no data available on this population in Cyprus. The purpose of the present study was (a) to examine the levels of ...

Aripiprazole IM depot as an option for the treatment of bipolar disorder.
https://doi.org/10.1080/14656566.2021.1910236
Expert Opinion on Pharmacotherapy; Kotzalidis GD, Rapinesi C et. al.

Apr 13th, 2021 - Introduction: Long-acting injectable (LAI) antipsychotic drugs are developed to reduce daily intake need and to overcome treatment non-adherence. Aripiprazole IM depot refers to two long-acting aripiprazole formulations, once monthly monohydrate (...

Schizophrenia hospitalization in the US 2005-2014: Examination of trends in demographic...
https://doi.org/10.1097/MD.0000000000025206
Medicine Chen E, Bazargan-Hejazi S et. al.

Apr 13th, 2021 - Primarily we aimed to examine the crude and standardized schizophrenia hospitalization trend from 2005 to 2014. We hypothesized that there will be a statistically significant linear trend in hospitalization rates for schizophrenia from 2005 to 201...

see more →

News  2,671 results

Discovery of Schizophrenia Gene Could Advance Research, Therapies
https://www.medscape.com/viewarticle/948198

Mar 25th, 2021 - A new genetic mutation in schizophrenia that blocks neuron communication in the brain may lead to novel treatment strategies and improve understanding of the mechanics of this disease. The discovery of this new gene, PCDHA3, could enhance the deve...

Blood Pressure Meds Tied to Increased Schizophrenia Risk
https://www.medscape.com/viewarticle/947713

Mar 17th, 2021 - Angiotensin-converting enzyme (ACE) inhibitors may be associated with an increased risk for schizophrenia and may affect psychiatric symptoms, new research suggests. Investigators found individuals who carry a genetic variant associated with lower...

CVD Risk Factors May Further Impair Cognition in Schizophrenia
https://www.medscape.com/viewarticle/947248

Mar 10th, 2021 - Risk factors for cardiovascular disease (CVD) are strongly associated with global cognitive impairment in patients with schizophrenia in new findings that suggest the need for an aggressive management approach. Investigators found that metabolic s...

'Landmark' Schizophrenia Drug in the Wings? 
https://www.medscape.com/viewarticle/946727

Mar 1st, 2021 - A novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent is associated with a greater reduction in psychosis symptoms compared with placebo, new research shows. In a randomized phase 2 trial comprised of nearly 200...

Inflammatory Immune Findings Likely in Acute Schizophrenia, MDD, Bipolar
https://www.medscape.com/viewarticle/946603

Feb 28th, 2021 - Researchers have come a long way in understanding the link between acute inflammation and treatment-resistant depression, but more work needs to be done, according to Mark Hyman Rapaport, MD. "Inflammation has been a hot topic in the past decade, ...

see more →

Patient Education  33 results see all →